Influence of Induction Therapy Using Basiliximab With Delayed Tacrolimus Administration in Heart Transplant Recipients ― Comparison With Standard Tacrolimus-Based Triple Immunosuppression ―
Open Access
- 25 November 2020
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 84 (12), 2212-2223
- https://doi.org/10.1253/circj.cj-20-0164
Abstract
Background:Appropriate indications and protocols for induction therapy using basiliximab have not been fully established in heart transplant (HTx) recipients. This study elucidated the influence of induction therapy using basiliximab along with delayed tacrolimus (Tac) initiation on the outcomes of high-risk HTx recipients. Methods and Results:A total of 86 HTx recipients treated with Tac-based immunosuppression were retrospectively reviewed. Induction therapy was administered to 46 recipients (53.5%) with impaired renal function, pre-transplant sensitization, and recipient- and donor-related risk factors (Induction group). Tac administration was delayed in the Induction group. Induction group subjects showed a lower cumulative incidence of acute cellular rejection grade ≥1R after propensity score adjustment, but this was not significantly different (hazard ratio [HR]: 0.63, 95% confidence interval [CI]: 0.37–1.08, P=0.093). Renal dysfunction in the Induction group significantly improved 6 months post-transplantation (P=0.029). The cumulative incidence of bacterial or fungal infections was significantly higher in the Induction group (HR: 10.6, 95% CI: 1.28–88.2, P=0.029). Conclusions:These results suggest that basiliximab-based induction therapy with delayed Tac initiation may suppress mild acute cellular rejection and improve renal function in recipients with renal dysfunction, resulting in its non-inferior outcome, even in high-risk patients, when applied to the appropriate recipients. However, it should be carefully considered in recipients at a high risk of bacterial and fungal infections.Keywords
This publication has 30 references indexed in Scilit:
- The Registry of the International Society for Heart and Lung Transplantation: Twenty-seventh official adult heart transplant report—2010The Journal of Heart and Lung Transplantation, 2010
- The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipientsThe Journal of Heart and Lung Transplantation, 2010
- Lower Risk of Infectious Deaths in Cardiac Transplant Patients Receiving Basiliximab Versus Anti-thymocyte Globulin as Induction TherapyThe Journal of Heart and Lung Transplantation, 2007
- Basiliximab and Rabbit Anti-thymocyte Globulin for Prophylaxis of Acute Rejection After Heart Transplantation: A Non-inferiority TrialThe Journal of Heart and Lung Transplantation, 2007
- Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart RejectionThe Journal of Heart and Lung Transplantation, 2005
- A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart TransplantationThe Journal of Heart and Lung Transplantation, 2005
- Induction Therapy with Basiliximab Allows Delayed Initiation of Cyclosporine and Preserves Renal Function After Cardiac TransplantationThe Journal of Heart and Lung Transplantation, 2005
- Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunctionThe Journal of Heart and Lung Transplantation, 2005
- Drug Therapy in the Heart Transplant RecipientCirculation, 2004
- POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS FOR BASILIXIMAB IN KIDNEY TRANSPLANTATIONTransplantation, 1999